reports
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHM...
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in bleeding, quality of life measures, and other ITP symptoms If approved, Wayrilz will be the first BTK inhibitor for ITP in the EU, targeting the root cause of the disease through multi-immune modulation Paris, October 17, 2025. The European Medicines Agency’s Committee ...
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour ê...
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire Recommandation fondée sur l’étude de phase 3 LUNA 3 démontrant une réponse plaquettaire rapide et durable, ainsi que des améliorations significatives en termes de saignements, de qualité de vie et d’autres symptômes de la TPI. S’il est approuvé, Wayrilz sera le premier inhibiteur de la BTK pour la TPI dans l...
Press Release: Sanofi provides update on regulatory review in the EU f...
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock (belumosudil) for the third-line treatment of adults and pediatric patients with chronic graft-versus-host disease (cGVHD). Sanofi will seek a re-examination of the CHMP op...
Communiqué de presse : Sanofi fournit une mise à jour de l’examen régl...
Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Paris le 17 octobre 2025. Le Comité des médicaments à usage humain (CHMP) de l’Agence européenne des médicaments a rendu un avis négatif concernant la demande d’autorisation de mise sur le marché du Rezurock (belumosudil) pour le traitement de troisième intention des adultes et ...
- Benoit Valleaux
- Steven Gould
- Thomas Zlowodzki
CON CONTINENTAL AKTIENGESELLSCHAFT
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
VOLV B VOLVO AB CLASS B
RI PERNOD RICARD SA
WTB WHITBREAD PLC
ABB ABB LTD.
RCO REMY COINTREAU SA
RXL REXEL SA
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
MRK MERCK KGAA
CLNX CELLNEX TELECOM S.A.
VACN VAT GROUP AG
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
CPR DAVIDE CAMPARI-MILANO N.V.
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
FER FERROVIAL SA
- Benoit Valleaux
- Steven Gould
- Thomas Zlowodzki
CON CONTINENTAL AKTIENGESELLSCHAFT
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
VOLV B VOLVO AB CLASS B
RI PERNOD RICARD SA
WTB WHITBREAD PLC
ABB ABB LTD.
RCO REMY COINTREAU SA
RXL REXEL SA
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
MRK MERCK KGAA
CLNX CELLNEX TELECOM S.A.
VACN VAT GROUP AG
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
CPR DAVIDE CAMPARI-MILANO N.V.
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
FER FERROVIAL SA
- Ana Arjona-Martinez
- Yan Derocles
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - September 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septembre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actio...
- Julian Dobrovolschi
PUB PUBLICIS GROUPE SA
GIVN GIVAUDAN SA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
ADEN ADECCO GROUP AG
LSEG LONDON STOCK EXCHANGE GROUP PLC
FHZN FLUGHAFEN ZURICH AG
RAND RANDSTAD NV
ZAL ZALANDO SE
RIO RIO TINTO PLC
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
AGN AEGON N.V.
- Julian Dobrovolschi
PUB PUBLICIS GROUPE SA
GIVN GIVAUDAN SA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
ADEN ADECCO GROUP AG
LSEG LONDON STOCK EXCHANGE GROUP PLC
FHZN FLUGHAFEN ZURICH AG
RAND RANDSTAD NV
ZAL ZALANDO SE
RIO RIO TINTO PLC
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
AGN AEGON N.V.
- Konrad Zomer
Heineken Holding N.V. reports transactions under its current share buy...
Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 13 October 2025 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025. From 6 October 2025 up to and including 10 October 2025 a total of 154,445 shares were repurchased on exchange at an average price of € 58.32. U...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary eff...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM showed prolonged and clinically meaningful benefits across PRRT-naïve and PRRT-exposed patients with unresectable or metastatic GEP-NETs, highlighting the potential of Target...
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’en...
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...) AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) AlphaMedixTM a démontré des bénéfices prolongés et cliniquement significatifs ...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary eff...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM showed prolonged and clinically meaningful benefits across PRRT-naïve and PRRT-exposed patients with unresectable or metastatic GEP-NETs, highlighting the potential of Targeted...
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’en...
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...) AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) AlphaMedixTM a démontré des bénéfices prolongés et cliniquement significatifs...
Heidelberg Materials AG: 1 director
A director at Heidelberg Materials AG bought 320 shares at 187.550EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Heineken Holding N.V. reports transactions under its current share buy...
Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 6 October 2025 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025. From 29 September 2025 up to and including 3 October 2025 a total of 185,825 shares were repurchased on exchange at an average price of € 58.32. ...
Legrand Signs Definitive Agreement to Acquire Avtron Power Solutions, ...
Legrand Signs Definitive Agreement to Acquire Avtron Power Solutions, a Global Provider of Load Banks & Power Quality Solutions WEST HARTFORD, Conn., Oct. 02, 2025 (GLOBE NEWSWIRE) -- , a global leader in electrical and digital building infrastructures, has signed a definitive agreement to acquire Cleveland, Ohio-based , a leading global provider of load banks and power quality solutions that serve a wide range of high-growth markets where reliable delivery of power is required. Avtron employs 600 people, operates five manufacturing sites across North America and Europe, and is expected t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.